国际肿瘤学杂志

国际肿瘤学杂志 ›› 2016, Vol. 43 ›› Issue (11): 826-828.doi: 10.3760/cma.j.issn.1673-422X.2016.11.006

• 论著 • 上一篇    下一篇

复方斑蝥胶囊联合同步放化疗在宫颈癌中的应用

邰云燕，潘东风，曹风军   

  1. 442000十堰，湖北医药学院附属人民医院肿瘤中心
  • 收稿日期:2016-01-22 出版日期:2016-11-08 发布日期:2016-11-02
  • 通讯作者: 曹风军，Email: 57460732@qq.com E-mail:57460732@qq.com

Appliation of compound mylabris capsules combined with concurrent chemoradiotherapy in cervical carcinoma

Tai Yunyan, Pan Dongfeng, Cao Fengjun   

  1. Cancer Center, Affiliated People′s Hospital of Hubei University of Medicine, Shiyan 442000, China
  • Received:2016-01-22 Online:2016-11-08 Published:2016-11-02
  • Contact: Cao Fengjun E-mail:57460732@qq.com

PDF

1479

被引次数

2

摘要： 目的观察复方斑蝥胶囊联合同步放化疗治疗局部晚期宫颈癌的临床疗效及不良反应。方法选取湖北医药学院附属人民医院肿瘤中心2013年9月—2014年9月期间收治的符合入组条件的80例ⅡB～ⅣA期宫颈癌患者，采用随机数字表法将研究对象分为观察组（n=40）和对照组（n=40）。观察组采用复方斑蝥胶囊联合同步放化疗，对照组采用单纯同步放化疗。同步放化疗中化疗方案采用TP方案即紫杉醇+顺铂，放疗采用适形调强放疗（IMRT）+腔内后装放疗。比较两组有效率、治疗期间Karnofsky功能状态（KPS）评分、急性不良反应。结果观察组与对照组近期有效率分别为97.5%和95.0%，差异无统计学意义（χ2=0.353，P=0.500）。观察组与对照组Ⅲ～Ⅳ级不良反应主要包括白细胞减少（80.0%∶95.0%）、血红蛋白降低（22.5%∶45.0%）、血小板减少（60.0%∶82.5%）、放射性膀胱炎（5.0%∶30.0%）及放射性直肠炎（10.0%∶30.0%），差异均有统计学意义(χ2=4.114，P=0.043；χ2=4.528，P=0.033；χ2=4.943，P=0.026；χ2=8.658，P=0.003；χ2=5.000，P=0.025)。治疗后观察组KPS评分中位值高于对照组（90分∶70分），差异有统计学意义(Z=4.523，P=0.000)。结论复方斑蝥胶囊联合同步放化疗与单纯同步放化疗治疗宫颈癌疗效相当，加入复方斑蝥胶囊能降低白细胞减少、血红蛋白降低、血小板减少、放射性直肠炎、放射性膀胱炎发生率，提高患者KPS评分，起到减毒作用。

关键词: 宫颈肿瘤, 放射疗法, 化学疗法, 辅助, 药物疗法

Abstract: ObjectiveTo observe the clinical efficacy and adverse reactions of compound mylabris capsules combined with concurrent chemoradiotherapy for patients with locally advanced cervical cancer. MethodsFrom September 2013 to September 2014, we collected 80 patients with stage ⅡBⅣA cervical cancer who were admitted to Cancer Center of Affiliated People′s Hospital of Hubei University of Medicine. They were divided into the observation group (n=40) and control group (n=40) according to random number table. Patients of observation group were treated with compound mylabris capsules combined with chemoradiotherapy, and patients of the control group were treated with the concurrent chemoradiotherapy alone. TP scheme of paclitaxel plus cisplatin was used in chemotherapy. Intensitymodulated radiation therapy (IMRT) and intracavitary brachytherapy was used in radiotherapy. The effective rates, Karnofsky Performance Status (KPS) scores, and recent adverse reactions in the two groups were compared. ResultsThe shorttime effective rates in the observation group and control group were 97.5% and 95.0% respectively, with no significant difference (χ2=0.346, P=0.556). The grade ⅢⅣ adverse reactions in the observation group and control group included  leucopenia (80.0% vs. 95.0%), lower hemoglobin (22.5% vs.45.0%), thrombocytopenia (60.0% vs. 82.5%), radioactive urocystitis (5.0% vs. 30.0%), radioactive proctitis (10.0% vs. 30.0%), with significant differences (χ2=4.114, P=0.043; χ2=4.528, P=0.033; χ2=4.943, P=0.026; χ2=8.658, P=0.003; χ2=5.000, P=0.025). The KPS score in the observation group was higher than that in the control group (90 vs. 70), with significant difference (Z=4.523, P=0.000). ConclusionThe clinical efficacy of compound mylabris capsules combined with concurrent chemoradiotherapy and chemoradiotherapy alone for patients with locally advanced cervical cancer are similar. Compound mylabris capsules can reduce the rates of adverse reactions such as leucopenia, lower hemoglobin, thrombocytopenia, radioactive urocystitis and radioactive proctitis, and can improve KPS score, which plays a role of reliving toxicity.

Key words: Uterine cervical neoplasms, Radiotherapy, Chemotherapy, adjuvant, Drug therapy